| Literature DB >> 30308089 |
Luigi Boccuto1, Ludovico Abenavoli2, Lauren Cascio1, Sujata Srikanth1, Barbara DuPont1, Andrew R Mitz3, Roger Curtis Rogers1, Katy Phelan4.
Abstract
The PNPLA3 gene maps in the 22q13 region and can have modifying effects on the phenotype of patients with Phelan-McDermid syndrome (PMS). The PNPLA3 p.I148M variant was detected in two PMS patients presenting with refractory seizures, gastrointestinal issues, and liver dysfunction. The p.I148M variant leads to macrovescicular steaosis and predisposes to liver disorders from steatohepatitis to fibrosis. Accumulation of lipid macrovescicles in the hepatocytes affects several pathways, including the metabolismof anti-epileptics, possibly leading to the lack of response to anti-epileptic treatments reported in the two cases. Screening for the p.I148M variant can identify PMS patients at higher risk for liver dyfunction and help designing personalized therapeutic protocols.Entities:
Mesh:
Substances:
Year: 2018 PMID: 30308089 DOI: 10.1111/cge.13451
Source DB: PubMed Journal: Clin Genet ISSN: 0009-9163 Impact factor: 4.438